Experimental drug shows promise for rare HIV-Linked cancer
NCT ID NCT05646082
First seen Apr 02, 2026 · Last updated Jun 15, 2026 · Updated 14 times
Summary
This early-stage study tests the safety of dostarlimab, an immunotherapy drug, in people with HIV-related Kaposi sarcoma that hasn't responded to standard HIV treatment. About 15-20 participants will receive the drug alongside their HIV therapy. The goal is to see if the drug is safe and can help the immune system fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HIV ASSOCIATED KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chelsea & Westminster Hospital
London, SW10 9NH, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.